The purpose of this study is to study the effect of a liraglutide, a glucagon-like peptide
agonist, on post-meal blood glucose concentrations, glucagon levels, mean weekly blood
sugars, and insulin doses in adolescents with Type 1 diabetes. Type 1 diabetes is an
autoimmune disease that is usually diagnosed before the age of 20. Individuals with this
disease are completely dependent on insulin for survival. While significant advances have
been made in technological support for improving diabetes control, insulin remains the only
effective treatment for Type 1 diabetes. Liraglutide is a long-acting glucagon-like peptide-1
analog. This drug is approved for the treatment of Type 2 diabetes in adults. This study will
test the effect of liraglutide on blood sugar control in adolescents with Type 1 diabetes.